The EU’s Pharmaceutical Legislation Reform
The European Union’s imminent pharmaceutical legislation reform aims to modernise its regulatory framework, focusing on improving patient access
Search results
We hope you find what you are looking for. Please let us know if we can assist you.
50 results found.
insight
insight
The European Parliament and the Council reach an agreement on European Health Data Space!
Towards a stronger European Health Union On March 15, 2024, the European Parliament and the Belgian Presidency of
insight
Commission proposes extension of IVDR transition periods for legacy products
The European Commission has on 23 January 2024 announced a proposal for an extension to the transition period
insight
Examining Off-label Medicine Use in Paediatric Healthcare
Our life science experts Dr Juli Mansnérus, Charlotta Bonsdorff and Petro Vornanen seized the opportunity to contribute to
insight
Life Sciences Commercialisation in Finland: Overview
A Q&A guide to life sciences commercialisation in Finland. This Q&A provides a high-level overview of key practical
insight
Life Sciences Regulation in Finland: Overview
A Q&A guide to life sciences regulation in Finland. This Q&A provides a high-level overview of key practical
insight
D&I Transaction Powerhouse Deal Announcement
Continued High Activity Level in H1/2023 for D&I Transaction Powerhouse
insight
D&I Transaction Powerhouse Deal Announcement
High Level of Activity Continues in 2022 for D&I Transaction Powerhouse
insight
The European pharmaceuticals legislation in transition – Finnish perspectives
As part of the EU’s aim to create a stronger European Health Union, the European Commission (“Commission”) published
insight
Towards greener patents and innovations: Is your IPR strategy aligned with your sustainability goals?
Sustainability is part of the strategy of every active company, irrespective of their business area. However, sustainability is